RxDoctor Payments Data

Swaroopa Rani Nalamalapu, MD

Critical Care Medicine · Waterloo, IANPI 1770947517

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,106 of the $1,599 with a category attached, or 69.2%. Olympus Corporation Of The Americas accounts for 72.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $1,114 and has fallen 93.4% since, to $73 in 2025.

$1,599in general payments, 2019–2025

Across 20 payments — averaging $79.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$1K
  • AstraZeneca$228
  • Intuitive Surgical$77
  • Medtronic$73
  • Insmed, Inc.$49
  • GSK$14

What the payments were for

  • Travel & lodging$1,10669%
  • Food & beverage$44428%
  • Education$493%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,599 in reported general payments places this provider in the 75th percentile of 33 critical care medicine providers in Iowa.

See all critical care medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$84,131
Medicare patients
218
Services billed
907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter170$119,387
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr56$31,581
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$19,680
Breo ElliptaFluticasone/Vilanterol33$19,635
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$12,515
SymbicortBudesonide/Formoterol Fumarate28$8,846
Advair HfaFluticasone Propion/Salmeterol16$7,877
Albuterol Sulfate HfaAlbuterol Sulfate98$3,126
Montelukast Sodium65$868
Fluticasone Propionate53$723
Azelastine Hcl13$646
Bupropion Hcl SrBupropion Hcl34$567
Azithromycin39$471
Famotidine51$468
Omeprazole14$315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$14$170,603259 claims
AstraZenecaBreztri Aerosphere, Symbicort$228$28,52656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 33 critical care medicine providers in Iowa.

Other critical care medicine in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →